FGC
MACK

Financial Gravity Companies’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Financial Gravity Companies’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$0 Hold
4
– – ﹤0.01% 1783
2017
Q4 		$0 Buy
+4
New +$37 ﹤0.01% 1544

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Gravity Companies's MACK Position: Q1 2018 in Review

Financial Gravity Companies held its Merrimack Pharmaceuticals, Inc. (MACK) position steady in Q1 2018 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1783.

Financial Gravity Companies first reported a position in MACK in Q4 2017 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

  • Financial Gravity Companies held 4 shares of Merrimack Pharmaceuticals, Inc. worth $0 as of Q1 2018.
  • Financial Gravity Companies left its Merrimack Pharmaceuticals, Inc. share count unchanged in Q1 2018.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of Financial Gravity Companies's portfolio in Q1 2018, its #1783 holding.
  • Financial Gravity Companies first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Financial Gravity Companies's 13F filing for Q1 2018, filed 4 May 2018.